geriatric medicine update n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Geriatric Medicine Update PowerPoint Presentation
Download Presentation
Geriatric Medicine Update

Loading in 2 Seconds...

  share
play fullscreen
1 / 22
cachet

Geriatric Medicine Update - PowerPoint PPT Presentation

155 Views
Download Presentation
Geriatric Medicine Update
An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Geriatric Medicine Update Dr Elena Mucci ConsultantPhysician/Geriatrician Leadership Tutor October 2013

  2. Is the approach to HTN in the elderly different?HYVET trial • HYVET: 3845 subjects, 80+ and functional – SBP > 160; goal 150/80 – Indapamide and ACEi vs. Placebo 30% reduction in all cause mortality • ABP Substudy (112 subjects at baseline) – Mean CBP 172/90 mm Hg – No orthostasis – Mean daytime ABP: 136/78 – Mean 24 hr ABP: 133/77 Beckett NS, NEJM, 2008; 358: 1887‐1898 Bulpitt CJ, Hypertension, 2013; 61: 89‐94

  3. Anticoagulation and Fall RiskShould we be prescribing anticoagulants inpatients with fall risk? • Prospective study ▫ 515 pts, median age 71, treated w/ vitamin K antagonists ▫ Fall risk associated with risk for major bleeding? ▫ High fall risk if: fall in past yr, gait/balance/mobility issue ▫ 60% were high risk • Outcomes ▫ No difference in time to first major bleeding event including fatal or intracranial within 12 months f/u. ▫ Risk for major bleed independently associated with polypharmacy. • 12% increased risk for each additional drug taken. Am J Med 2012. PMID: 22840664

  4. Anticoagulation and Fall Risk • Take Home Point: ▫ Patient > 65 yrs with CHADS2 score of 2-3 would have to fall 295 times yearly for risk of fall-related SDH to outweigh benefits of stroke prevention. ▫ Polypharmacy greater risk. ▫ Use this opportunity to stop unnecessary medications.

  5. Aspirin to prevent recurrent DVT • Recurrence of unprovoked VTE after stopping anticoagulants ▫ 5-15% at one year, 30-50% at 5-10 yrs ▫ Highest risk: male, mod-severe post-thrombotic syndrome, proximal DVT, elevated D-dimer3-4 weeks after stopping therapy. • Extending anticoagulants associated with increased risk of bleeding. • Is the use of low dose aspirin an alternative?

  6. Low Dose Aspirin for prevention of recurrent DVT • Double blind placebo controlled RCTs • WARFASA (402 pts) and ASPIRE (822 pts) Trials ▫ Pts with first unprovoked VTE who stopped anticoagulation after 6-18 months of therapy. ▫ Randomized to ASA 100 mg daily vs. Placebo • VTE recurrence ▫ Pooled data from both trials ▫ 32% reduction in rate of recurrent VTE ▫ 34% reduction in rate of major vascular events ▫ Low risk of bleeding NEJM 2012. PMID: 22621626, 23121403, 231 21404

  7. Update on drugs commonly used in the Elderly • Omeprazole impairs absorption of calcium, iron, and levothyroxine • Omeprazole is a cause of acute interstitial nephritis • Omeprazole can cause B12 deficiency • Omeprazole contributes to C Dif and delays recovery • Fenofibrate and losartan significantly lower serum uric acid levels • Longterm use of metformin may result in significant B12 deficiency • Trimethoprim causes reversible elevation of serum creatinine and potassium

  8. AF and new anticoagulatnts • Dabigatran, direct Thrombin inhibitor, 110mg BD; 150 mg BD, 75mg BD if eGFR 15-30, renal excretion. Non inferior to warfarin. • Rivaroxaban, 10a inhibitor, 20mg OD, 15mg OD in renal disease, also licensed for PE/DVT, renal/liver excretion. Non inferior to warfarin. • Apixaban, 10a inhibitor, 5mg BD and 2.5 mg BD, mainly liver excretion-safer in renal disease. The only one which showed reduction in all cause mortality, including reduction in major bleeding, GI bleeding-no difference.

  9. AF, rate control • RACE II • Goal heart rate <80bpm vs. <110bpm • Permanent atrial fibrillation • <80 years of age • Resting atrial fibrillation rate >80bpm • Primary outcome composite: – Death from cardiovascular causes – Hospitalization for heart failure – Stroke or systemic embolism – Major bleeding – Arrhythmic events including syncope or VT – Implantation of pacemaker or ICD • Van Gelder et al. NEJM 2010;362:1363-1373 2011 ACC/AHA Updates • Treatment to a goal resting heart rate <80bpm is not beneficial compared to <110bpm in patients with atrial fibrillation who have LVEF >40% and no or minimal symptoms (Class III)

  10. Treatment Options • Beta-blockers-sympathetic pathway – Carvedilol less effective than others • Verapamil-Diltiazem • Digoxin-As adjunct only-parasympathetic pathway – Use if heart failure also • Amiodarone-Rarely for rate control • AV node ablation and pacing

  11. Diastolic DysfunctionHFpEF • Prevalence: increasing with the aging population and increasing recognition • Systolic HF: CAD, HTN, DM • Diastolic HF: Age, Female, HTN, Obesity • Precipitating factors: labile HTN, Med noncompliance,Dietnon-compliance, • Iatrogenenic (NSAIDS, fluids), Infections

  12. HFpEF • Treatment: • Class I: • Control of BP (<130/80) • Agents not specified • Control of tachycardia in Afib • Reduction of central blood volume-with diuretics • Class IIa: coronary revascularization if ischemic • Class IIb: • Restoration of NSR • Digitalis use not well established • ACE/ARB/BB/CCB

  13. Medications Used to Treat Hallucinations,Delusions and Agitation • Antipsychotics (Black Box Warning!) – Haloperidol – Risperidone – Olanzapine – Quetiapine • Anticonvulsants – Carbamazepine • Antidepressants – Sertraline • Β-adrenergic receptor antagonists – Propanolol • Antianxiety agents – Clonazepam, lorazepam

  14. Statin induced Myopathy • Myalgia • Normal CK, reduce the dose, try different drug, stop the drug, restart at lower dose or different one. • Myositis • Elevated CK, stop the drug till CK/symptoms normalised, restart with a statin with high half life, like Rosuvastatin+/- Co-Enzyme Q10. • Rhabdomyalisis • CK 10 times the normal level, myoglobinuria, AKI, death. Stop statin and never use again.

  15. Continuation of donepezil in patients with moderate-to‐severe Alzheimer’s disease may improve cognition at 52 weeks. • RCT • 295 community-dwelling patients, mean age 77.1; 65% females; 95% white, mean MMSE 9; taking Donepezil for at least 3 months. • 4 groups: • Continue donepezilwith placebo memantine • Continue donepezil and starting memantine • Discontinue donepezil with placebo memantine • Discontinue Donepezil an starting Memantine Follow up period 52 weeks Outcome measures: Cognition (SMMSE) and functional status (BADLS) Howard R, McShane R, Lindesay J, Ritchie C et al. Donepezil and Memantine for Moderate-Severe Alzheimer’s Disease. N Engl J Med. 2012 Mar 8;366(10):893-903.

  16. Continuation of donepezil in patients with moderate-to‐severe Alzheimer’s disease may improve cognition at 52 weeks. • Clinically important difference • SMMSE of 1.4 points or more • BADL score of 8 points or more • Donepezil v no Donepezil: 1.9 points difference on SMMSE and 3.0 points difference on BADLS. • Memantine v no Memantine: 1.2 points and 1.5 points difference respectively • No difference Donepezil+Memantine

  17. Clinical Bottom Lines • NICE 2011: treatment should be continued only when it is considered to be having a worthwhile effect on cognitive, global, functional or behavioural symptoms. • This study suggests that cognitive outcomes can be improved with continuing Donepezil treatment. • What do I do: • If patient is on Donepezil I continue • If not on any treatment I start on Memantine • If on Donepezil and developed severe behavioural problems I stop Donepezil and start Memantine • I stop everything in the EoLC

  18. Medications to treat mooddisorders in dementia • Selection of antidepressant usually based on previous response to the drug: – trazodone (50mg at bedtime) – sedating and useful with agitated depression and insomnia – also consider nortriptyline 10mg at bedtime – Sertraline 25-50mg per day (proven effective in clinical trials, may especially be useful with agitated depression) • May see improvement in sleep and agitation soon after instituting therapy but full relief of depression delayed by 4-6 weeks

  19. Medications to treat sleepdisturbances • Trazodone50-100mg pobedtime • Quetiapine begin with 12.5mg bedtime but can work up the dose. Use only if sleep disturbance is severe and associated with agitation. • Avoid usual sleep medications such as zopiclone

  20. Medications to treat apathy • May try a low dose of methylphenidate (5– 10mg early morning but never after 2pm) • If depressed, may try a more stimulating antidepressant such as fluoxetine (10mg to begin with)

  21. Tight control of DM in NH eligible older adults may be associated with poor outcomes • Cohort study • 367 NH patients with DM, mean age 80 (+/-9) • 67% female. Almost one-third on oral and 50% on insulin, 79% cognitive impairment , mean ADLs 8, follow up 2 years • Outcome measures: functional decline and death at 2 years • 4 groups: less than 7%, 7-8%, 8-9% and over 9% Yau, C. GlycosylatedHb and Functional Decline in Community-Dwelling NH-Eligible Elderly Adults with DM. J Am Geriatr Soc. 2012 Jul;60(7):1215-21

  22. Clinical bottom lines • HbA1c level of 8-9% appears to be associated with less functional decline or death at 2 years • Current AGS recommends AbA1c target of 8.0% or less for frail elderly adults with limited life expectancy may be lower than necessary to maintain function and delay death for this vulnerable population. • ADA Position Statement suggests a patient-centred approach in the management of type 2 DM and recommends less stringent HbA1c goals. • Although this study was conducted in NH patients, it suggests that clinicians should consider less aggressive glycaemic targets when managing vulnerable older adults.